Infectious Diseases and Vaccines

Solutions to navigate complex clinical trials

Partner with skilled medical, clinical, regulatory and operational teams in the design, planning, implementation and sound delivery of infectious disease and vaccine programs.

Leverage our powerful alliances with academic and community-based healthcare organizations, and advocacy groups with access to underserved and at-risk populations.

Integrate our progressive digital innovation and mobile health solutions to reduce site and patient burden, increase speed and improve your data quality.

Driving global success in infectious disease prevention and treatment

The continued rise in difficult-to-treat infections and deaths caused by multi-drug resistant pathogens and COVID-19 and its variants reinforces the need to develop more safe, robust and effective therapies and vaccines. To protect people across the globe, particularly those who have inadequate access to medical care, our team is dedicated to advancing products that help prevent and treat bacterial, viral, fungal and parasitic infections in community-based and critical care settings. 

Learn how our infectious disease and vaccine experts bring together decades of experience from large pharma, biotech and research organizations—spanning nonclinical and clinical development of products—to efficiently support your program.

Experience matters when choosing a partner.

We've worked on more than 310 infectious disease and vaccine studies within the past five years alone—including COVID-19—and leverage this expertise to shape optimal strategies for you. 

In the last 5 years


Infectious Disease and Vaccine Studies





Top indications

Acute Respiratory Illnesses

  • COVID-19
  • Community-acquired bacterial pneumonia (CABP)
  • Influenza
  • Respiratory syncytial virus (RSV)
  • Other respiratory viruses

In-Hospital Studies

  • COVID-19
  • Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
  • Sepsis
  • Acute respiratory distress syndrome (ARDS)

Bacterial Infections

  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Staphylococcus aureus bacteremia
  • Complicated urinary tract infections (cUTI)
  • Periprosthetic joint infection (PJI)
  • Diabetic foot ulcer (DFU)

Chronic Viral Infections

  • Hep B
  • Hep C
  • HIV

Attacking emerging pathogens through optimal drug development

With research rapidly advancing and new emerging paradigms for disease prevention and treatment, navigating the competitive development landscape for new vaccines and therapies requires:

  • Innovative solutions to ensure efficient provision of safety and efficacy endpoints
  • Support to enable effective regulatory consultation and submission
  • Scalable vaccine resourcing solutions
  • Customized digital health solutions
  • Partnerships with sites and advocacy groups

Count on our expertise and holistic suite of services, tools and technologies to help rapidly move your new product through the development cycle. 

Meet the team

We have successfully partnered with biopharmaceutical and device companies to bring multiple assets to market including three of the last four antibiotics, as well as vaccines against COVID-19 and RSV. We are relentless in our promise to provide you guidance and help deliver new vaccines and treatments.

Comprehensive solutions to accelerate the development of your asset

As your partner, we’ll serve as an extension of your team, meeting your specific needs and working effectively to integrate cross-functional knowledge. From preclinical immunology and proof-of-concept studies to larger Phase II/III clinical trials and post-approval studies, we’ll apply our vast scientific and operational experience to support the development of your infectious disease vaccine and therapy.

Get in touch to learn more about our solutions designed to expeditiously advance your asset through clinical and regulatory milestones. 

최신 소식 받기:
Fortrea 뉴스 및 공지사항을 구독하세요.